is a public-owned biopharmaceutical company, founded in 2005 in Cadiz, developing and roducing biomedical products for the pharmaceutical and veterinarian sectors. Bionaturis specializes in the prevention and treatment of niche diseases, such as orphan diseases.
Bionaturis was established in 2005, in the academic environment of the University of Cadiz, and strengthened its strategic presence by locating its research laboratory, development and innovation (R&D+I) in the Centro Andaluz de Biologia de Desarrollo (CABD) University Pablo de Olavide (Seville).
Bionaturis counted with the support of the venture company Univen Capital in its development phase, as well as the
contributions of the regional governments.
Faced with a pharmaceutical sector that finds itself in a restructuring process, Bionaturis is presented as a real alternative to lead new market opportunities, while offering new hope to millions of patients worldwide with currently no effective treatment. To hit these new markets, Bionaturis shows a new concept in the development of biopharamaceuticals, called FLYLIFE®.
Bionaturis has chosen Nature as an optimized source for the production of biopharmaceuticals, substituting the traditional industrial cumbersome steel reactors for single use, disposable and naturally occurring individual reactors.
FLYLIFE® makes use of natural resources to achieve and indeed surpass the productive capacity of traditional industry standards but utilizing up to tenfold less space and fifteen-fold less investment. Amongst others, in niche markets where currently there is no solution, these competitive advantages provide a profitable solution and gives
renewed hope to millions of worldwide patients. With this new manufacturing concept,
Bionaturis perfectly adapts to new trends that are reshaping the pharmaceutical and veterinary sectors, and thus completing its mission to lead the alternative systems of production of biological drugs.
Bionaturis: pipeline and competitive advantages Today, besides a line of high-quality contract services, Bionaturis has its own pipeline in various stages of development:
1. BNT001. A new version (biobetter) of human recombinant glucocerebrosidase, aimed at people diagnosed with Gaucher disease. Just in Spain there are 256 people diagnosed with this illness, with the average cost of treatment worth of 300 000 EUR/person/year. The value propositions of this biobetter are: cost-saving treatment, a more patient-friendly way of administration (oral delivery), and the possibility of extending treatment to patients with Gaucher type II and III. . International patent application in force until 2029.
2. BNT004. The first vaccine on the market for the prevention and eradication of intestinal nematode infection in cattles. This disease causes annual losses worth of 5,500 millon ½ in the sector worldwide. International patent application in force until 2029.
2. BNT005. The first prophylactic and therapeutic vaccine in the market against visceral canine leishmaniasis, a disease with increasing zoonotic episodes in children lately.
Bionaturis has an exclusive license right of an international patent in force until 2031, with an estimated global market of 220 million ½.
Member of the Board of the Association of Biotechnology Companies in Andalusia (Bioandalucía) and a trustee of the Technological Corporation of Andalusia.
Managing Director Javier Gallastegui. Diploma in Business Administration and Bachelor of Laws (ICADEMADRID). MBA in finance and international marketing from the University of San Francisco (USA). Twenty years of experience into the pharmaceutical sector with responsibilities in general management, sales, strategic analysis and licenses. Commercial Director of Nycomed Spain for two years. Managing Director of the pharmaceutical company Daiichi-Sankyo Spain for twelve years and Managing Director of Veterinary Specialties Vetoquinol in Spain and Portugal for two years.